Global pharmaceutical company, Pfizer, announced another big move in August 2016.  They now have an agreement to acquire the development and commercialization rights to AstraZeneca's late-stage small-molecule antibiotics business.  The portfolio comprises the approved antibiotics Merrem, Zinforo and Zavicefta, along with ATM-AVI and CXL that are in clinical development. The rights are mostly global, with some territory reservations – frequently for North America.

This big purchase follows the recent announcement that Pfizer was acquiring Medivation for [Content redacted, and available only to subscribers]

AstraZeneca is a British-Swedish multinational pharmaceutical and biologics company headquartered in London.  The company focuses on discovery, development and commercialization of prescription medicines.  Its market cap was just under REDACTED as of August 26, 2016.

Pfizer’s corporate headquarters is in the U.S. and it has a global portfolio of medicines and vaccines, along with well-known health care products.  Household names such as Advil®, Nexium®, Centrum®, Robitussin® and ChapStick® are all Pfizer’s.  Its market cap was REDACTED as of August 26, 2016.

Featured image copyright: Kateryna Kon and Shutterstock ID: 380193295

Sources available to LER subscribers only